Your browser doesn't support javascript.
COVID-19 seroprevalence in Pakistan: a cross-sectional study.
Ahmad, Ahsan M; Shahzad, Khurram; Masood, Mariumn; Umar, Maida; Abbasi, Fahad; Hafeez, Assad.
  • Ahmad AM; Center for Global Public Health- Pakistan, Health Services Academy, Ministry of National Health Services Regulations and Coordination, Opposite National Institute of Health (NIH) Chak Shahzad, Islamabad, Pakistan.
  • Shahzad K; Health Services Academy, Ministry of National Health Services Regulations and Coordination, Islamabad, Pakistan.
  • Masood M; Health Services Academy, Ministry of National Health Services Regulations and Coordination, Islamabad, Pakistan msmasood148@gmail.com.
  • Umar M; Health Services Academy, Ministry of National Health Services Regulations and Coordination, Islamabad, Pakistan.
  • Abbasi F; Health Services Academy, Ministry of National Health Services Regulations and Coordination, Islamabad, Pakistan.
  • Hafeez A; Health Services Academy, Ministry of National Health Services Regulations and Coordination, Islamabad, Pakistan.
BMJ Open ; 12(4): e055381, 2022 04 06.
Article in English | MEDLINE | ID: covidwho-1779374
ABSTRACT

OBJECTIVES:

This study adapted WHO's 'Unity Study' protocol to estimate the population prevalence of antibodies to SARS CoV-2 and risk factors for developing SARS-CoV-2 infection.

DESIGN:

This population-based, age-stratified cross-sectional study was conducted at the level of households (HH).

PARTICIPANTS:

All ages and genders were eligible for the study (exclusion criteria contraindications to venipuncture- however, no such case was encountered). 4998 HH out of 6599 consented (1 individual per HH). The proportion of male and female study participants was similar. PRIMARY AND SECONDARY OUTCOME

MEASURES:

Following were the measured outcome measures- these were different from the planned indicators (i.e. two out of the three planned indicators were measured) due to operational reasons and time constraints -Primary indicators Seroprevalence (population and age specific).Secondary indicators Population groups most at risk for SARS-CoV-2-infection.

RESULTS:

Overall seroprevalence of SARS-CoV-2 antibodies was 7.1%. 6.3% of individuals were IgG positive while IgM positivity was 1.9%. Seroprevalence in districts ranged from 0% (Ghotki) to 17% (Gilgit). The seroprevalence among different age groups ranged from 3.9% (0-9 years) to 10.1% (40-59 years). There were no significant differences in the overall seroprevalence for males and females. A history of contact with a confirmed COVID-19 case, urban residence and mask use were key risk factors for developing SARS-CoV-2 infection.

CONCLUSIONS:

This survey provides useful estimates for seroprevalence in the general population and information on risk factors for developing SARS-CoV-2 infection in the country. It is premised that similar studies need to be replicated at the population level on a regular basis to monitor the disease and immunity patterns related to COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Child, preschool / Female / Humans / Male Country/Region as subject: Asia Language: English Journal: BMJ Open Year: 2022 Document Type: Article Affiliation country: Bmjopen-2021-055381

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Child, preschool / Female / Humans / Male Country/Region as subject: Asia Language: English Journal: BMJ Open Year: 2022 Document Type: Article Affiliation country: Bmjopen-2021-055381